Stoke Therapeutics, Inc.

DB:0GT Stock Report

Market Cap: €571.5m

Stoke Therapeutics Valuation

Is 0GT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0GT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0GT (€10.9) is trading below our estimate of fair value (€52.34)

Significantly Below Fair Value: 0GT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0GT?

Key metric: As 0GT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0GT. This is calculated by dividing 0GT's market cap by their current revenue.
What is 0GT's PS Ratio?
PS Ratio35.7x
SalesUS$16.74m
Market CapUS$599.06m

Price to Sales Ratio vs Peers

How does 0GT's PS Ratio compare to its peers?

The above table shows the PS ratio for 0GT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.3x
FYB Formycon
13.5x33.4%€821.0m
BIO3 Biotest
1.6x6.0%€1.4b
MOR MorphoSys
10.2xn/a€2.6b
HPHA Heidelberg Pharma
11.9x16.6%€101.1m
0GT Stoke Therapeutics
35.8x50.2%€614.9m

Price-To-Sales vs Peers: 0GT is expensive based on its Price-To-Sales Ratio (35.8x) compared to the peer average (9.5x).

Price to Sales Ratio vs Industry

How does 0GT's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
0GT 35.7xIndustry Avg. 8.0xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 0GT is expensive based on its Price-To-Sales Ratio (35.8x) compared to the European Biotechs industry average (7.8x).

Price to Sales Ratio vs Fair Ratio

What is 0GT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0GT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio35.7x
Fair PS Ratio16.9x

Price-To-Sales vs Fair Ratio: 0GT is expensive based on its Price-To-Sales Ratio (35.8x) compared to the estimated Fair Price-To-Sales Ratio (17x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0GT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€10.60
€20.76
+95.9%
29.9%€32.61€13.97n/a7
Nov ’25€11.20
€20.28
+81.1%
30.9%€32.06€12.82n/a7
Oct ’25€10.80
€20.28
+87.8%
30.9%€32.06€12.82n/a7
Sep ’25€12.40
€20.28
+63.6%
30.9%€32.06€12.82n/a7
Aug ’25€13.60
€20.46
+50.4%
30.9%€32.34€12.93n/a7
Jul ’25€12.30
€20.59
+67.4%
30.9%€32.54€13.02n/a7
Jun ’25€12.50
€20.59
+64.7%
30.9%€32.54€13.02n/a7
May ’25€10.90
€20.57
+88.7%
30.5%€32.31€12.92n/a7
Apr ’25€13.00
€20.44
+57.3%
31.5%€32.32€12.00n/a7
Mar ’25€7.05
€17.54
+148.8%
48.2%€32.32€5.54n/a7
Feb ’25€4.38
€17.54
+300.5%
48.2%€32.32€5.54n/a7
Jan ’25€4.80
€17.67
+268.0%
47.4%€31.98€5.48n/a7
Dec ’24€3.40
€17.67
+419.6%
47.4%€31.98€5.48n/a7
Nov ’24€3.54
€20.75
+486.0%
34.0%€33.01€12.26€11.207
Oct ’24€3.52
€19.42
+451.7%
37.3%€32.76€11.23€10.808
Sep ’24€5.10
€19.16
+275.7%
34.9%€31.93€10.95€12.409
Aug ’24€5.95
€19.83
+233.3%
29.5%€31.55€10.82€13.609
Jul ’24€9.45
€23.51
+148.8%
23.6%€32.20€11.04€12.309
Jun ’24€10.30
€23.78
+130.9%
22.3%€32.36€11.10€12.5010
May ’24€7.80
€23.24
+198.0%
23.1%€31.90€10.94€10.9010
Apr ’24€7.35
€25.68
+249.4%
29.4%€37.91€8.53€13.0010
Mar ’24€8.25
€31.32
+279.7%
54.5%€77.15€8.37€7.0510
Feb ’24€8.95
€31.32
+250.0%
54.5%€77.15€8.37€4.3810
Jan ’24€8.35
€33.25
+298.2%
47.7%€77.51€18.68€4.8010
Dec ’23€7.10
€38.41
+441.0%
49.5%€80.30€19.35€3.4010
Nov ’23€14.80
€47.00
+217.6%
37.7%€84.07€24.31€3.5410

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Teva Pharmaceutical Industries

US$19.3b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$16.20

7D

2.2%

1Y

88.4%

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$705.00

7D

-7.1%

1Y

-3.8%

Merck

US$246.5b

Operates as a healthcare company worldwide.

6MK

US$93.40

7D

0.3%

1Y

-0.4%